Search

Search Constraints

You searched for: Author/Creator Kaplow, June

Search Results

1. A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid. (7th December 2020)

3. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021)

5. DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY. (1st July 2019)

6. DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE. (1st July 2006)

7. IC‐P‐040: EVALUATION OF TAU DEPOSITION IN AMYLOID POSITIVE MCI OR MILD‐AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

8. O4‐11‐02: The path to regulatory qualification of cerebrospinal fluid biomarkers as enrichment tools in clinical trials of patients with early Alzheimer's disease: For the coalition against major diseases. (1st July 2015)

9. O4‐12‐05: EVALUATION OF TAU DEPOSITION IN AMYLOID‐POSITIVE MCI OR MILD AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

10. P1‐040: ELENBECESTAT, A NOVEL BACE INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS AND TOLERABILITY IN JAPANESE SUBJECTS WITH MULTIPLE DOSINGS. (1st July 2006)